India has stepped up regulatory action against the growing misuse of GLP-1-based weight loss medications, following concerns about their widespread and often unsupervised availability.
The Ministry of Health and Family Welfare has directed stricter monitoring across the pharmaceutical supply chain to ensure patient safety and prevent unethical practices.
The Drugs Controller General of India has significantly strengthened oversight mechanisms to curb the unauthorised sale and promotion of GLP-1 drugs.
The government stated:
“Regulatory surveillance will continue to be intensified in the coming weeks and non-compliances will be dealt strictly with actions including cancellation of licenses, penalties, and prosecution under applicable laws,”
Authorities are ensuring that pharmaceutical companies, distributors, and healthcare providers adhere to ethical standards in the sale and promotion of these medications.
Officials have flagged the growing availability of GLP-1 drugs through:
Experts warn that using such drugs without medical supervision can lead to severe side effects and long-term health complications.
To tackle misleading marketing, the government issued a directive on March 10, 2026.
According to the ministry:
“On March 10, 2026, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label usage,”
The move aims to prevent companies from promoting drugs for unapproved uses, particularly for cosmetic weight loss.
In recent weeks, enforcement actions have been intensified across the country.
Authorities have also issued notices to entities found violating regulations.
GLP-1 drugs, also known as Glucagon-Like Peptide-1 receptor agonists, are a class of medications primarily used to treat type 2 diabetes and, in certain cases, obesity. According to the NCBI (StatPearls) reference, these drugs mimic the action of a natural hormone called GLP-1, which is released in the body after eating and plays a key role in regulating blood sugar and appetite.
In India, GLP-1 drugs such as semaglutide, liraglutide, dulaglutide, and exenatide are prescribed under strict medical supervision, typically by endocrinologists or internal medicine specialists. These medications work by increasing insulin secretion when blood sugar levels are high, while simultaneously reducing glucagon release—a hormone that raises blood sugar. They also slow down gastric emptying, meaning food stays longer in the stomach, which helps control appetite and supports weight loss.
One of the major reasons for the rising popularity of GLP-1 drugs in India is their dual benefit. Apart from improving glycaemic control, they promote weight reduction and may also reduce cardiovascular risks in patients with diabetes. Studies have shown that these drugs can lower HbA1c levels (a key diabetes marker) and contribute to modest but consistent weight loss.
However, their use is not without risks. Common side effects include nausea, vomiting, and gastrointestinal discomfort, while more serious concerns such as pancreatitis or gallbladder issues may arise in rare cases. Due to these risks, regulatory authorities in India emphasize that GLP-1 drugs should only be used under proper medical guidance.
In summary, GLP-1 drugs represent an important advancement in modern metabolic treatment. In India, they are increasingly being adopted for diabetes and weight management, but their safe and effective use depends on careful prescription, monitoring, and patient awareness.
The drug regulator, in partnership with state authorities, has launched targeted operations to identify malpractice across the supply chain.
GLP-1 drugs in India are approved only under strict medical supervision.
This ensures that the drugs are used safely and for appropriate medical conditions such as diabetes and obesity management.
Authorities have reiterated that misuse of GLP-1 drugs can result in:
Citizens are strongly advised to use these medications only under the supervision of qualified medical professionals.
Globally, GLP-1 receptor agonists such as Semaglutide and Liraglutide have gained popularity for weight management and diabetes treatment.
The rising demand, especially for cosmetic weight loss, has led to increased scrutiny by regulators worldwide, including in India.
The government’s decision to intensify surveillance on GLP-1-based weight loss drugs reflects a proactive approach to safeguarding public health amid rising misuse and commercialisation. While these medications offer significant benefits when used appropriately, their unregulated availability and off-label promotion pose serious risks. By tightening inspections, enforcing strict penalties, and promoting responsible prescribing practices, authorities aim to strike a balance between accessibility and safety. Going forward, sustained regulatory vigilance, combined with public awareness, will be crucial in ensuring that such advanced therapies are used ethically and effectively, without compromising patient well-being.